Microcore has more than two decades of experiences in research, manufacturing and scale up of many Nutra-bioceuticals and Therapeutics. Lactobacillus sporogenes is the previous name for Bacillus coagulans, a unique spore-forming, lactic acid producing probiotic widely recognized for its stability, safety, and effectiveness.
Unlike traditional Lactobacillus strains that are sensitive to heat, moisture, and stomach acidity, Bacillus coagulans forms resilient spores that protect the organism during processing, storage, and gastrointestinal transit. This spore-coating ensures exceptional stability and survivability, allowing it to reach the intestine alive, where it germinates, produces L-lactic acid, and helps restore a healthy balance of intestinal microflora.
Lactobacillus sporogenes (Bacillus coagulans) is highly significant due to its exceptional stability and proven clinical effectiveness. Its spore-forming nature allows it to withstand heat, acidity, and mechanical stress during manufacturing and GI transit.
It is utilized extensively in clinical and nutritional applications, including the management of gastrointestinal disorders such as antibiotic-associated diarrhea, infectious diarrhea, IBS, and IBD. It is also incorporated into pediatric formulations to alleviate digestive disturbances like colic and constipation due to its established safety profile.
MRL 1025 offers exceptional resistance to heat, moisture, and acidic environments, ensuring superior survival. Once germinated, it produces antimicrobial compounds that suppress pathogenic microorganisms and promote microbial balance. It is highly advantageous for nutraceuticals as it requires no refrigeration.
MRL 1025 exerts its effects through multiple mechanisms: lowering intestinal pH via L-lactic acid, synthesizing bacteriocins to suppress harmful flora, upregulating tight-junction proteins for barrier integrity, and modulating immune responses by increasing secretory IgA levels.
The developments are at lab scale and expected to complete clinical studies and further launch by 2028.